The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
COMMENTARY
With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
By Tomoyuki Iwasaki The health ministry’s study group on counterfeit drugs will meet again this autumn. In its interim report announced in June, the study group noted that the establishment of domestic rules consistent with global PIC/S GDP guidelines on…
To read the full story
Related Article
- Counterfeit Drug Panel OKs Final Report, MHLW to Issue GDP Guidelines in FY2018
December 27, 2017
- MHLW Counterfeit Drug Panel Agrees on “Voluntary” Introduction of GDP in Japan
November 14, 2017
- MHLW Study Group Compile Draft Interim Report on Preventing Distribution of Counterfeit Drugs
June 12, 2017
COMMENTARY
- Hopes to Nix Budget Ceiling Dashed, How Will Industry Get Its Message Across to Govt?
September 4, 2023
- Chuikyo Embracing Industry Opinions in Early Phase of Drug Pricing Debate
August 29, 2023
- Can “G1” Withdrawal Scheme Be Improved Enough to Serve Its Purpose?
August 23, 2023
- Study Group of LDP Heavyweights Eyes “Drug Discovery Agency”
August 7, 2023
- Expert Panel Report Failed to Delve into Annual Price Cuts, Irking Pharma Officials
June 30, 2023
As Japan moves into elaborate discussions on the potential reform of its cost-effectiveness assessment (CEA) in FY2024, members of a…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
The Japanese government on September 12 approved Moderna’s updated monovalent COVID-19 vaccine directed at the Omicron XBB.1.5 strain, following its…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…